Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization (IS) (2020 - 2025)

Vivos Therapeutics has reported Depreciation & Amortization (IS) over the past 6 years, most recently at $442000.0 for Q4 2025.

  • Quarterly Depreciation & Amortization (IS) rose 206.94% to $442000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 125.3% year-over-year, with the annual reading at $1.3 million for FY2025, 125.3% up from the prior year.
  • Depreciation & Amortization (IS) was $442000.0 for Q4 2025 at Vivos Therapeutics, up from $384000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (IS) peaked at $442000.0 in Q4 2025 and troughed at $144000.0 in Q4 2024.
  • The 5-year median for Depreciation & Amortization (IS) is $172000.0 (2022), against an average of $197550.0.
  • Year-over-year, Depreciation & Amortization (IS) fell 26.0% in 2023 and then surged 206.94% in 2025.
  • A 5-year view of Depreciation & Amortization (IS) shows it stood at $168000.0 in 2021, then increased by 0.6% to $169000.0 in 2022, then dropped by 11.83% to $149000.0 in 2023, then dropped by 3.36% to $144000.0 in 2024, then surged by 206.94% to $442000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Depreciation & Amortization (IS) are $442000.0 (Q4 2025), $384000.0 (Q3 2025), and $306000.0 (Q2 2025).